This study explores how the gut microbiota influences immune responses during toxin-induced CNS demyelination. While microbiota modulates inflammatory pathways, it has limited effects on the actual remyelination process.
The findings highlight the distinct roles of microbiota in inflammatory versus regenerative phases of CNS damage. Targeting microbiota composition could offer therapeutic benefits for reducing inflammation without impairing remyelination.
These results underscore the potential of microbiome-based interventions in managing CNS diseases like multiple sclerosis, where inflammation drives tissue damage.
